Novel Dermal Micro-Coring® Device Holds Promise For Moderate To Severe Wrinkle
As seen in Dermatology News
An investigative dermal Micro-Coring® device designed for improvement of moderate to severe facial wrinkles and tightening is poised to become a game-changer in the minimally invasive aesthetics field…
Read More
The New Non-Surgical Facelift: Can Dermal Micro-Coring® Come Close To Surgery?
The Next 25 Years In Beauty
As seen in Marie Claire
“In 2 years, you won’t need surgery to give your face a lift”… The Cytrellis treatment “is like a facelift by a thousand small cuts instead of a few big ones, but there’s no scarring and the results are subtler,” says Dr. Mathew Avram, faculty director of the Dermatology Laser and Cosmetic Center at Massachusetts General Hospital. “Trials are underway now.”
Read More
Cytrellis Completes $28.5 Million Series B Financing
Cytrellis announced today that it has received $28.5 million in a Series B round which included existing investors ARCH Venture Partners, the Merz Venture Initiative and new investors, Partner Fund Management and Biomatics Captial.
Read More
Cytrellis Clinical Results Recently Presented At 2018 ASLMS Conference
Dr. Roy Geronemus, director of the Laser & Skin Surgery Center of New York, recently presented findings from Cytrellis’ multi-center study of 23 women who were treated bilaterally in the mid and lower face, using Cytrellis’ proprietary device.
Read More
Merz Pharma Announces New Investment In Cytrellis Biosystems
Merz Pharma has made a strategic investment in Cytrellis Biosystems, a US based company developing a new class of non-surgical products to combat sagging skin associated with aging.
Read More